Q
In children with a first unprovoked afebrile seizure, what is the prognosis in terms of overall mortality and sudden unexplained death in epilepsy? METHODS Design: inception cohort followed for mean 14 years.
Setting: 3 medical centres in Bronx, New York, USA.
Patients: 407 children who were 1 month to 19 years of age {mean age at first seizure 6.8 y}* with a first unprovoked afebrile seizure. 68 (17%) had initial seizure of remote symptomatic aetiology and 339 (83%) had initial seizure of cryptogenic or idiopathic aetiolgy.
Prognostic factors: no prognostic factors included.
Outcomes: overall mortality and sudden unexplained death in epilepsy.
*Data reported in Ann Neurol 2000;48:140-7.
MAIN RESULTS
9 children (2.2%) died. 5 deaths were classified as definitely or probably unrelated to epilepsy. 4 deaths were classified as possible or probable sudden unexplained deaths in epilepsy, with all 4 children having previous seizures and anticonvulsant use at the time of death.
CONCLUSION
In children with a first unprovoked afebrile seizure, 9 children (2.2%) died, 4 of whom had deaths classified as possible or probable sudden unexplained deaths in epilepsy. This study by Shinnar et al is important in examining the risk of mortality in children who have had a first, unprovoked seizure, with the general practice of no treatment for first seizures. Only 4 of 9 deaths in 407 children with unprovoked seizures were related to recurrent seizures, and all were already receiving AED treatment because of recurrent seizures. Thus, delaying treatment until a second seizure does not seem to increase the risk of sudden death. This study involves the same 407 children reported earlier by the same investigators, 2 on seizure recurrence. In the earlier report, 46% of the children had a recurrent seizure within 10 years. After a second seizure, 72% had a third seizure, showing that the second seizure is a more valid indicator for a diagnosis of epilepsy and initiation of antiepileptic treatment.
The most important limitation of the study is the small sample size; children with epilepsy have a low mortality rate, and sudden death in epilepsy is a relatively rare occurrence. It is, therefore, questionable whether a sample size of 407 children is a large enough number to reach a definite conclusion on the influence of delay of treatment on the incidence of sudden death. It should reassure clinicians, however, that delay of treatment until after a second seizure in this study did not seem to carry any increased risk.
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